AI Article Synopsis
- Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) shows greater antitumor effects compared to standard paclitaxel, but clinical trials indicate varying rates of side effects like neuropathy and neutropenia.
- A study on rats found that repeated doses of nab-paclitaxel significantly increased pain sensitivity, specifically mechanical and cold allodynia, more than standard paclitaxel.
- These findings highlight the need for careful monitoring of neuropathic side effects when using nab-paclitaxel in cancer treatments.
Article Abstract
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel. However, in a clinical trial, higher and lower rates of peripheral neuropathy and neutropenia were observed. In this study, we compared the effects of nab-paclitaxel and standard paclitaxel on pain behaviors in rats. Repeated administration of nab-paclitaxel dose-dependently induced both mechanical and cold allodynia, and the effects of nab-paclitaxel on pain behaviors tended to be stronger than that of standard paclitaxel at the doses used clinically. These results suggest that closer attention must be paid to the neuropathy when administering nab-paclitaxel in clinical settings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1254/jphs.11062sc | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!